REN and diabetic kidney disease: Finerenone, a selective non-steroidal mineralocorticoid receptor antagonist, in combination with inhibitors of the renin angiotensin aldosterone system, has been shown to be effective in reducing albuminuria in patients with diabetic nephropathy (117).